Androgen receptor reverts dexamethasone‑induced inhibition of prostate cancer cell proliferation and migration

Guo,Ju; Ma,Ke; Xia,Hai‑Mei; Chen,Qing‑Ke; Li,Lei; Deng,Jun; Sheng,Jing; Hong,Yan‑Yan; Hu,Jie‑Ping

doi:10.3892/mmr.2018.8566

Androgen receptor reverts dexamethasone‑induced inhibition of prostate cancer cell proliferation and migration

Authors:
- Ju Guo
- Ke Ma
- Hai‑Mei Xia
- Qing‑Ke Chen
- Lei Li
- Jun Deng
- Jing Sheng
- Yan‑Yan Hong
- Jie‑Ping Hu
View Affiliations

Affiliations: Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250355, P.R. China, Department of Anesthesiology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Nursing, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China
Published online on: February 6, 2018 https://doi.org/10.3892/mmr.2018.8566
Pages: 5887-5893
Copyright: © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to determine the role of androgen receptor in the effect of dexamethasone on cell proliferation and migration of multiple prostate cancer cells. The prostate cancer cell lines LNCaP, 22Rv1, C4‑2 and PC3 were cultured in vitro. For glucocorticoid‑induced experiments, the cells were transferred and cultured in RPMI‑1640 medium with 10% charcoal‑stripped serum from RPMI‑1640 medium with 10% fetal bovine serum for at least 24 h. The effects of dexamethasone on the proliferation and migration of various cell lines were analyzed by MTT and migration assays. Dexamethasone exhibited no effect on LNCaP, C4‑2 and 22Rv1 cell lines, but suppressed proliferation of glucocorticoid receptor (GR)+ androgen receptor (AR)‑ PC3 cell line. Dexamethasone suppressed PC3 cell migration, and did not affect migration of PC3‑AR9 cells. Dexamethasone positively or negatively regulated proliferation of various prostate cancer cells based on AR and GR expression profiles. The data presented in the present study indicates that androgen receptor reverts the dexamethasone‑induced inhibition of prostate cancer cell proliferation and migration.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
2	Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, Tannock I, Drake CG and de Bono JS: Prostate cancer. Lancet. 387:70–82. 2016. View Article : Google Scholar : PubMed/NCBI
3	Perner S, Cronauer MV, Schrader AJ, Klocker H, Culig Z and Baniahmad A: Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer. Oncotarget. 6:35542–35555. 2015. View Article : Google Scholar : PubMed/NCBI
4	Saad F and Fizazi K: Androgen deprivation therapy and secondary hormone therapy in the management of hormone-sensitive and castration-resistant prostate cancer. Urology. 86:852–861. 2015. View Article : Google Scholar : PubMed/NCBI
5	Nguyen PL, Alibhai SM, Basaria S, D'Amico AV, Kantoff PW, Keating NL, Penson DF, Rosario DJ, Tombal B and Smith MR: Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 67:825–836. 2015. View Article : Google Scholar : PubMed/NCBI
6	Tagawa ST, Posadas EM, Bruce J, Lim EA, Petrylak DP, Peng W, Kheoh T, Maul S, Smit JW, Gonzalez MD, et al: Phase 1b study of abiraterone acetate plus prednisone and docetaxel in patients with metastatic castration-resistant prostate cancer. Eur Urol. 70:718–721. 2016. View Article : Google Scholar : PubMed/NCBI
7	Teply BA, Luber B, Denmeade SR and Antonarakis ES: The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 19:72–78. 2016. View Article : Google Scholar : PubMed/NCBI
8	Nishimura K, Nonomura N, Satoh E, Harada Y, Nakayama M, Tokizane T, Fukui T, Ono Y, Inoue H, Shin M, et al: Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst. 93:1739–1746. 2001. View Article : Google Scholar : PubMed/NCBI
9	Yemelyanov A, Czwornog J, Chebotaev D, Karseladze A, Kulevitch E, Yang X and Budunova I: Tumor suppressor activity of glucocorticoid receptor in the prostate. Oncogene. 26:1885–1896. 2007. View Article : Google Scholar : PubMed/NCBI
10	Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, et al: Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 155:1309–1322. 2013. View Article : Google Scholar : PubMed/NCBI
11	Isikbay M, Otto K, Kregel S, Kach J, Cai Y, Vander Griend DJ, Conzen SD and Szmulewitz RZ: Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer. 5:72–89. 2014. View Article : Google Scholar : PubMed/NCBI
12	Narayanan S, Srinivas S and Feldman D: Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy. Nat Rev Urol. 13:47–60. 2016. View Article : Google Scholar : PubMed/NCBI
13	Xie N, Cheng H, Lin D, Liu L, Yang O, Jia L, Fazli L, Gleave ME, Wang Y, Rennie P and Dong X: The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors. Int J Cancer. 136:E27–E38. 2015. View Article : Google Scholar : PubMed/NCBI
14	Venkitaraman R, Lorente D, Murthy V, Thomas K, Parker L, Ahiabor R, Dearnaley D, Huddart R, De Bono J and Parker C: A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer. Eur Urol. 67:673–679. 2015. View Article : Google Scholar : PubMed/NCBI
15	Hu J and Chen Q: The role of glucocorticoid receptor in prostate cancer progression: From bench to bedside. Int Urol Nephrol. 49:369–380. 2017. View Article : Google Scholar : PubMed/NCBI
16	Song C, Kim Y, Min GE and Ahn H: Dihydrotestosterone enhances castration-resistant prostate cancer cell proliferation through STAT5 activation via glucocorticoid receptor pathway. Prostate. 74:1240–1248. 2014. View Article : Google Scholar : PubMed/NCBI
17	Wen S, Shang Z, Zhu S, Chang C and Niu Y: Androgen receptor enhances entosis, a non-apoptotic cell death, through modulation of Rho/ROCK pathway in prostate cancer cells. Prostate. 73:1306–1315. 2013. View Article : Google Scholar : PubMed/NCBI
18	Kan SF, Huang WJ, Lin LC and Wang PS: Inhibitory effects of evodiamine on the growth of human prostate cancer cell line LNCaP. Int J Cancer. 110:641–651. 2004. View Article : Google Scholar : PubMed/NCBI
19	Wu KK: Analysis of protein-DNA binding by streptavidin-agarose pulldown. Methods Mol Biol. 338:281–290. 2006.PubMed/NCBI
20	Ramamoorthy S and Cidlowski JA: Exploring the molecular mechanisms of glucocorticoid receptor action from sensitivity to resistance. Endocr Dev. 24:41–56. 2013. View Article : Google Scholar : PubMed/NCBI
21	Yuan S, Trachtenberg J, Mills GB, Brown TJ, Xu F and Keating A: Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. Cancer Res. 53:1304–1311. 1993.PubMed/NCBI
22	Hu J, Wang G and Sun T: Dissecting the roles of the androgen receptor in prostate cancer from molecular perspectives. Tumour Biol. 39:10104283176922592017. View Article : Google Scholar : PubMed/NCBI
23	Paliouras M and Diamandis EP: An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines. Biol Chem. 389:773–780. 2008. View Article : Google Scholar : PubMed/NCBI
24	Yano A, Fujii Y, Iwai A, Kageyama Y and Kihara K: Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res. 12:3003–3009. 2006. View Article : Google Scholar : PubMed/NCBI
25	Attardi BJ, Burgenson J, Hild SA and Reel JR: Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells. Mol Cell Endocrinol. 222:121–132. 2004. View Article : Google Scholar : PubMed/NCBI
26	Hartig SM, He B, Newberg JY, Ochsner SA, Loose DS, Lanz RB, McKenna NJ, Buehrer BM, McGuire SE, Marcelli M and Mancini MA: Feed-forward inhibition of androgen receptor activity by glucocorticoid action in human adipocytes. Chem Biol. 19:1126–1141. 2012. View Article : Google Scholar : PubMed/NCBI
27	Stechschulte LA and Sanchez ER: FKBP51-a selective modulator of glucocorticoid and androgen sensitivity. Curr Opin Pharmacol. 11:332–337. 2011. View Article : Google Scholar : PubMed/NCBI
28	Jääskeläinen T, Makkonen H and Palvimo JJ: Steroid up-regulation of FKBP51 and its role in hormone signaling. Curr Opin Pharmacol. 11:326–331. 2011. View Article : Google Scholar : PubMed/NCBI
29	Storlie JA, Buckner JC, Wiseman GA, Burch PA, Hartmann LC and Richardson RL: Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer. 76:96–100. 1995. View Article : Google Scholar : PubMed/NCBI
30	Nishimura K, Nonomura N, Yasunaga Y, Takaha N, Inoue H, Sugao H, Yamaguchi S, Ukimura O, Miki T and Okuyama A: Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer. 89:2570–2576. 2000. View Article : Google Scholar : PubMed/NCBI
31	Morioka M, Kobayashi T, Furukawa Y, Jo Y, Shinkai M, Matsuki T, Yamamoto T and Tanaka H: Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone. Urol Int. 68:10–15. 2002. View Article : Google Scholar : PubMed/NCBI
32	Venkitaraman R, Thomas K, Huddart RA, Horwich A, Dearnaley DP and Parker CC: Efficacy of low-dose dexamethasone in castration-refractory prostate cancer. BJU Int. 101:440–443. 2008.PubMed/NCBI
33	Kume H, Suzuki M, Fujimura T, Fukuhara H, Enomoto Y, Nishimatsu H, Ishikawa A and Homma Y: Docetaxel as a vital option for corticosteroid-refractory prostate cancer. Int Urol Nephrol. 43:1081–1087. 2011. View Article : Google Scholar : PubMed/NCBI
34	Shamash J, Powles T, Sarker SJ, Protheroe A, Mithal N, Mills R, Beard R, Wilson P, Tranter N, O'Brien N, et al: A multi-centre randomised phase III trial of dexamethasone vs dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: Immediate vs deferred diethylstilbestrol. Br J Cancer. 104:620–628. 2011. View Article : Google Scholar : PubMed/NCBI
35	Hodson R: Small organ, big reach. Nature. 528:S118–S119. 2015. View Article : Google Scholar : PubMed/NCBI
36	Zheng Y, Izumi K, Li Y, Ishiguro H and Miyamoto H: Contrary regulation of bladder cancer cell proliferation and invasion by dexamethasone-mediated glucocorticoid receptor signals. Mol Cancer Ther. 11:2621–2632. 2012. View Article : Google Scholar : PubMed/NCBI